Discover the Latest in Biomedical Research Innovation

Reviewers examining 100 clinical papers found 65% needed revisions just to explain what their statistical tests were for, and 64% had omitted effect sizes entirely. Statistical reporting problems are rarely about running the wrong analysis; they're about not writing down enough for a reader to judge it. Here's what belongs in the section, built on the SAMPL guidelines: seven things to state in your methods, the results formats that draw fewest queries, and a template you can

Run an ANCOVA and a multiple regression on the same data, specified equivalently, and you get the same F, the same p, and the same coefficients. They are one model with two traditions, and dummy coding is the bridge. So the real question isn't which is correct but which framing makes your result clearest. This piece covers why they're equivalent, what genuinely differs, and how to describe your model so reviewers from either tradition can follow it.

Hunted through Prism's Analyze menu for ANCOVA? It isn't there, and GraphPad's own FAQ confirms they've never shipped one. Prism can still do it, through two documented routes most users never find: the simple-linear-regression slopes test for the parallel-slopes assumption, and multiple regression with dummy-coded groups for the adjusted comparison. Here are both step by step, plus an honest comparison with describing the same analysis in plain language instead.

Most bench scientists reach for a t-test or ANOVA by reflex, but plenty of real experiments have a continuous dose, groups that differ at baseline, or nuisance variation eating the power. Multiple regression handles all three, and ANOVA and ANCOVA turn out to be special cases of it. This guide covers when regression earns its place, how to read coefficients honestly, the two covariate mistakes that invalidate an analysis, and why dose-response needs a 4PL curve, not a line.

Your treated and control wells started at different confluence, so comparing endpoints with a plain ANOVA measures your treatment effect plus the head start. ANCOVA fixes that by adjusting for a continuous covariate, and usually buys power too. This step-by-step ANCOVA protocol runs 24 numbered steps from covariate choice through reporting, with the assumption checks in the order they need to happen, including the parallel-slopes test most people skip.

An audit of 200 published animal studies found only 22% had replicated the right thing, and 46% counted repeated measurements of one biological unit as independent samples. That error, pseudoreplication, inflates your n, shrinks your error bars, and manufactures significance that won't replicate. Here's what separates technical vs biological replicates, why the mistake inflates false positives, and what actually counts as a biological replicate in cell culture.

A no-fluff, step-by-step scratch assay imaging protocol for images your software can actually measure. Twenty-six numbered steps take you from pixel calibration and Köhler alignment, through Time 0 capture with locked exposure, to returning to identical fields at later time points. Includes an equipment table, an acceptance-criteria checklist to run before you analyze, and a troubleshooting table mapping every common symptom to the step that fixes it.

When medical residents were surveyed on interpreting a p-value, 88% were confident they understood it and 100% got it wrong. That gap is why p-value mistakes survive peer review: nobody thinks they're making one. This piece covers the five most common errors in biomedical papers, several measured at scale in real journals: the inverse probability fallacy, the replication fallacy, 'trending toward significance', p-hacking, and treating 0.05 as a bright line.

A no-fluff, step-by-step cell imaging protocol for microscopy images you can actually quantify. Eighteen numbered steps take you from Köhler setup and pixel calibration, through setting exposure on your brightest sample so nothing saturates, to acquiring the whole set under locked, identical settings. Works for brightfield, phase contrast, and fluorescence. Includes an equipment table, an acceptance-criteria checklist, and a troubleshooting table mapping each symptom to the s

Your p-value can confirm an effect is real and say nothing about whether it's big enough to matter. Effect size answers that second question, and for a two-group comparison Cohen's d is the standard measure: the mean difference divided by the pooled standard deviation. This guide covers how to calculate and report Cohen's d, why to report it alongside every p-value and confidence interval, and how to interpret it without leaning on the 0.2/0.5/0.8 benchmarks that often don't

A perfect scratch becomes unusable if the field drifts out of focus, the illumination shifts between time points, or the wound edges are too low-contrast to segment. The biggest scratch assay imaging mistakes aren't dramatic failures, they're small inconsistencies that quietly distort wound area. This guide covers the imaging principles behind reproducible wound healing assays on any microscope: imaging mode, objectives, Köhler illumination, and locking your optics.

Sophie 4.5 is live. It keeps everything that made 4.0 work and sharpens what matters: the core chat is ~40% more intelligent at the same speed, and the Regulatory Architect is 3x faster, ~25% smarter, and now wired directly into the CFR database for more accurate device classification. The Visualizer and Analytics engines get intelligence and speed bumps, and a wave of UI/UX updates came straight from how people used 4.0. Here's everything new in CLYTE's Sophie 4.5.

You asked to get CytCut onto your bench now instead of waiting, so here it is. CytCut 3.5 is available for immediate order at $36, in 24- and 48-well, the same wound healing assay tool that turns minutes of pipette scratching into seconds of consistent, reproducible wounds. It's UV- and alcohol-sanitizable with a 3–6 month working life. The autoclavable CytCut 4.0 is still on track for end of September at $99 pre-order. Order 3.5 with code cytcut352673 for $15 off through Jul

SD, SEM, and 95% CI are three different error bars answering three different questions, and they're not interchangeable. The standard error vs standard deviation confusion is where most figures go wrong: SEM is always the smallest, so it makes data look tighter than it is, which is why reviewers flag it most. This piece explains what each bar actually claims, shows one dataset drawn three ways, and tells you which to use, and when to just report SD with your n.

The statistics were the easy part; then you lost an afternoon nudging axis labels, adding error bars and significance stars, and redrawing schematics in Illustrator. Sophie's Visualizer, CLYTE's scientific illustration engine, lives in the same chat where you analyze your data, so you just describe the figure you want and get it publication-ready in seconds: data charts, experimental-design schematics, and mechanism diagrams. We walk through turning one finished analysis into

Walk into most labs and you'll find a multi-seat GraphPad Prism license that only one or two people can actually use. Prism is powerful, but its learning curve takes months, so the license sits idle while everyone waits on the lab's 'stats person.' This piece makes the case for a different GraphPad Prism alternative: Sophie, the AI you just talk to. Describe your experiment in plain English and it picks the right test, runs it, and explains the result.

A small p-value tells you a difference is probably real, not that it's big enough to matter. Statistical significance asks whether an effect is distinguishable from noise; biological significance asks whether it's large enough to change a cell, a patient, or a conclusion. Because the p-value shrinks as your sample grows, a big enough study can stamp p < 0.05 on a difference that means nothing. Here's why, with real examples, and what to report instead: effect size and confide

A former FDA reviewer ran a test for us. He took a real problem — a device with an endotoxin level his team couldn't lower — and tried to bait four AIs into approving a workaround he knew was wrong. One by one, ChatGPT, Gemini, and Claude came around and told him to proceed. Sophie refused: it cited the guidelines, held the line when he pushed, and sent him to the FDA. In regulated work, an AI eager to agree is a liability. Here's what happened — plus a test you can run yours

We took notes at NY Tech Week 2026. In an a16z masterclass, Deel's Anish Acharya and Shuo Wang made the case that the most defensible AI is built where decisions carry liability — the ground a model can't own. IBM's Gary Cohn added the data-sovereignty argument for small, specialized, walled-off models. For an AI built for FDA-regulated biomedical research, that's the whole thesis. Here's what we took from the week — and the a16z session is now a podcast on our channel.

Stop losing valuable ChIP data during library prep! Our Ultimate Guide to ChIP-seq Library Preparation covers everything from "Standard" protocols to "Ultra-Low Input" strategies. Learn how to eliminate adapter dimers, choose between NEBNext vs. MicroPlex, and master the art of ChIPmentation. Perfect for researchers struggling with low yields or high duplication rates. Read the full protocol optimization guide now!